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WHAT THIS PAPER ADDS
 This study is the ﬁrst to demonstrate that the presence of circulating N 3HcyLys isopeptide (a degradation product of homo-
cysteinylated proteins) in peripheral artery disease (PAD) patients with hyperhomocysteinemia during administration of folic acid
that effectively reduces tHcy is associated with the PAD progression and an increased risk of cardiovascular events. Moreover, in
PAD, circulating N 3HcyLys isopeptide is associated with elevated asymmetric dimethylarginine (ADMA) levels, enhanced
oxidative stress and impaired ﬁbrinolysis reﬂected by increased plasminogen activator inhibitor-1 (PAI-1).a r t i c l e i n f o
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Objective: Folic acid (FA) administration can reduce plasma total homocysteine (tHcy); however, it fails to
decrease cardiovasculareventsandprogressionofperipheral arterydisease (PAD).N 3ehomocysteinylelysine
isopeptide (N 3eHcyeLys) is formed during catabolism of homocysteinylated proteins. We sought to inves-
tigate factors that determine the presence of N 3eHcyeLys in PAD patients with hyperhomocysteinemia
receiving FA.
Patients and methods: We studied 131 consecutive PAD patients with tHcy > 15 mmol l1 taking FA
0.4 mg d1 for 12 months. Serum N 3eHcyeLys was determined by high-performance liquid chroma-
tography (HPLC). We also measured interleukin-6 (IL-6), plasminogen activator inhibitor-1 (PAI-1),
asymmetric dimethylarginine (ADMA) and 8-iso-prostaglandin F2a (8-iso-PGF2a).
Results: FA administration resulted in a 70.5% decrease in tHcy (p< 0.0001). However, serum N 3eHcyeLys
was detectable in 28 (21.4%) patients on FA who were more frequently current smokers and survivors of
ischaemic stroke (p < 0.001). They had higher tHcy by 46.0%, PAI-1 by 51.7%, 8-iso-PGF2a by 59.1% and
ADMA by 26.4% (all, p < 0.0001). The presence of N 3eHcyeLys was associated with lower ankle-brachial
index (ABI) values (p < 0.001) and higher prevalence of cardiovascular events (p < 0.001) following
therapy.
Conclusion: The presence of N 3eHcyeLys in one-ﬁfth of hyperhomocysteinemic individuals with PAD
despite FA treatment is associated with progression of PAD and with increased ADMA formation,
oxidative stress and hypoﬁbrinolysis.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.ology, Jagiellonian University
land. Tel.: þ48 12 6143004;
s).
ciety for Vascular Surgery. PublishPeripheral artery disease (PAD) results in narrowing of large-
and medium-sized arteries in lower extremities, and is associated
with an increased risk of myocardial infarction (MI) and stroke.1
Estimated prevalence of PAD, deﬁned as an ankle-brachial index
(ABI) of 0.90, ranges from 2.5% in the age group 50e59 years to
14.5% in subjects >70 years.2 Risk factors for PAD are similar toed by Elsevier Ltd. All rights reserved.
Abbreviations
ABI ankle-brachial index
ACEI angiotensin-converting enzyme inhibitor
ADMA asymmetric dimethylarginine
CAD coronary artery disease
CRP C-reactive protein
FA folic acid
HPLC high-performance liquid chromatography
IL-6 interleukin-6
8-iso-PGF2a 8-iso-prostaglandin F2a
LDL low-density lipoprotein
MI myocardial infarction
N 3eHcyeLys N 3ehomocysteinylelysine isopeptide
PAD peripheral artery disease
PAI-1 plasminogen activator inhibitor-1
tHcy total homocysteine
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20e50% of the PAD patients.3 Potential markers of PAD progression
include C-reactive protein (CRP), proinﬂammatory cytokines,
ﬁbrinogen, D-dimer, tissue plasminogen activator, plasminogen
activator inhibitor-1 (PAI-1), together with 8-iso-prostaglandin F2a
(8-iso-PGF2a), asymmetric dimethylarginine (ADMA), and total
homocysteine (tHcy).4e6
Elevated plasma tHcy is associated with an increased risk of
vascular events, but trials failed to show clinical beneﬁts from Hcy-
lowering therapy in cardiovascular patients.7
Homocysteine can be metabolised to Hcyethiolactone, a reac-
tive thioester that causes protein N-homocysteinylation, that may
impair or alter protein function.8,9 N 3ehomocysteinyleLysine
(N 3eHcyeLys), an isopeptide generated during proteolytic degra-
dation of N 3eHcyeproteins, has recently been identiﬁed.10
N 3eHcyeLys is elevated in acute MI.11 Circulating concentrations
of this isopeptide are related to plasma ADMA, a nitric oxide (NO)
synthase inhibitor, which is formed by methylation of protein L-
arginine residues.11,12 ADMA has been reported to be an indepen-
dent risk marker for all-cause and cardiovascular death in PAD
patients.13 A large meta-analysis showed that patients with PAD
had higher Hcy levels than those observed in controls without
PAD.14 Folic acid (FA) supplementation reduces plasma tHcy and
improves ABI, but it does not reduce cardiovascular risk among
subjects with prior history of vascular disease.15,16
We tested the hypothesis that N 3eHcyeLys isopeptide is present
in a subset of hyperhomocysteinemic individuals with PAD despite
FA treatment and that this phenomenon is associated with
progression of PAD. We also sought to determine factors that are
linked with the presence of measurable N 3eHcyeLys levels.Patients and Methods
Patients
Consecutive patients with PAD, deﬁned as an ABI  0.9
measured using established methods and hyperhomocysteinemia,
deﬁned as plasma Hcy concentration 15 mmol l1 were recruited
to the study (n ¼ 131). All eligible patients denied taking any
vitamin preparations within the 6 months preceding the enrol-
ment. The exclusion criteria were: a history of venous thrombo-
embolism, recent (<6 months) arterial thrombotic event,
angioplasty or surgery, active cancer, liver cirrhosis, renal failure
(serum creatinine >177 mmol l1), any acute illness, current anti-
coagulant therapy. CAD was deﬁned as a history of MI, coronaryrevascularisation, or hospitalisation for angina symptoms. Diabetes
and stroke were diagnosed according to the World Health Orga-
nisation (WHO) criteria. Hypercholesterolaemia was deﬁned as
a low-density lipoprotein (LDL) cholesterol >3.0 mmol l1 or total
cholesterol >5 mmol l1 or treatment with cholesterol-lowering
medication.17 An individual was classiﬁed as having arterial
hypertension if he/she met one of the following criteria: (1)
previous history of hypertension; (2) current antihypertensive
treatment; (3) systolic or diastolic pressure 140 mmHg or
90 mmHg, respectively, on at least two different occasions. Heart
failure was diagnosed in subjects with decreased left ventricular
ejection fraction <50% on echocardiography. Chronic obstructive
pulmonary disease was deﬁned as forced expiratory volume in 1 s
divided by forced vital capacity below 70% of normal values.
All recruited patients received the treatment with FA 0.4 mg
once daily. They were asked not to change their diet and abstain
from vitamin supplements throughout the study period. All
subjects were followed for 1 year. None of the patients were lost to
follow-up. Four patients declared quitting smoking. Clinical and
laboratory parameters were collected after one year of FA treat-
ment. We deﬁned the progression of PAD as decrease in ABI of
>0.15 during the treatment. Other clinical end points were a new
MI or stroke during follow-up.
The study was approved by the Jagiellonian University Ethical
Committee, and all patients provided written informed consent.
Laboratory investigations
Prior to the onset of FA administration and following 1 year of
the therapy, blood was drawn from an antecubital vein with
minimal stasis after an overnight fast between 8 and 10 AM. Platelet
count, glucose, lipid proﬁle and creatinine were assayed by routine
laboratory techniques. Fibrinogenwas determined using the Clauss
method and CRP by the latex nephelometry (Dade Behring, Mar-
burg, Germany).
tHcy, cysteine and gluthatione (GSH) in plasma were assayed by
high-performance liquid chromatography (HPLC) as described.18
Serum folate levels were measured using a commercial kit
(Abbott Laboratories). Commercially available immunoenzymatic
assays were used to determine PAI-1 (American Diagnostica,
Greenwich, CT, USA), 8-iso-PGF2a (Cayman Chemicals, Ann Arbor,
MI, USA) and interleukin-6 (IL-6) (R&D Systems, Abingdon, UK). All
parameters were measured in duplicate by an investigator blinded
to the sample origin. Plasma ADMA was assayed by HPLC as
described.19 Intra-assay and inter-assay coefﬁcients of variation
were <8%.
After 12 months of FA administration, serum N 3eHcyeLys levels
were assayed using the method by G1owacki et al.10,20 The limit of
quantiﬁcation is 0.1 mmol l1. Intra-assay and inter-assay coefﬁ-
cients of variation were 4.3 and 7.5%, respectively.
Statistical analysis
Continuous variables were presented as mean  standard
deviation or median and quartiles as appropriate. Categorical
variables were presented as percentages. The ShapiroeWilk test
was used to assess the normality of continuous variables. To
examine the differences between two independent groups
Student’s t-test (for normally distributed variables) or
ManneWhithey test (for non-normally distributed variables) were
used. The Fisher exact test was employed when both variables were
categorical. To assess linear dependence between variables the
Pearson correlation coefﬁcient (Pearson’s r) for normally distrib-
uted variables or Spearman’s rank correlation coefﬁcient (Spear-
man’s rho) for non-normally distributed variables were calculated.
Table 1
Baseline characteristics of PAD patients classiﬁed into two groups based on N 3eHcyeLys levels after FA treatment.
Variable The whole group
n ¼ 131
Patients with detectable
N 3-Hcy-Lys n ¼ 28
Patients with undetectable
N 3-Hcy-Lys n ¼ 103
p-value
Age, years 60 (55e65) 61 (56e67,5) 59 (55e65) 0.38
Male sex, n (%) 107 (82) 23 (82) 84 (82) 0.99
BMI, kg/m2 27.1 (24.7e29) 27.5 (25.6e28.9) 26.9 (24.5e29) 0.51
ABI 0.72 (0.63e0.81) 0.76 (0.67e0.81) 0.71 (0.62e0.81) 0.61
Diabetes mellitus, n (%) 37 (28) 11 (39) 26 (25) 0.34
History of myocardial
infarction, n (%)
70 (53) 18 (64) 52 (50) 0.21
History of PCI, n (%) 45 (34) 12 (43) 33 (32) 0.37
Stroke, n (%) 14 (11) 10 (36) 4 (4) <0.0001
Heart failure, n (%) 13 (10) 2 (7) 11 (11) 0.21
COPD, n (%) 43 (33) 6 (21) 37 (36) 0.18
Hypercholesterolaemia, n (%) 110 (84) 24 (86) 86 (84) 0.99
Current smoking, n (%) 51 (39) 24 (86) 27 (26) <0.0001
Arterial hypertension, n (%) 104 (79) 22 (79) 82 (80) 0.99
Medication
Aspirin, n (%) 124 (95) 27 (96) 97 (94) 0.40
b-blocker, n (%) 84 (64) 20 (71) 64 (62) 0.41
Statin, n (%) 128 (98) 28 (100) 100 (97) 0.11
Calcium antagonist, n (%) 44 (34) 8 (29) 36 (35) 0.65
ACEI, n (%) 85 (65) 14 (50) 71 (69) 0.08
Data shown as mean  SD (Student’s t-test) or as median (IQR; ManneWhitney U test) or number (percentage; Fisher’s exact test). Abbreviations: BMI, Body Mass Index;
COPD, Chronic obstructive pulmonary disease; PCI, percutaneous coronary intervention; ABI, ankle-brachial index; ACEI, angiotensin-converting enzyme inhibitors.
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ables adjusted for potential confounders (age, gender, body mass
index (BMI), current smoking, positive stroke history and pre-
treatment folate concentrations) were analysed by multiple linear
regressions. The independent predictors of N 3eHcyeLys were
identiﬁed using a stepwise multivariate Firth’s logistic regression.
Firth’s logistic regression was used to obtain odds ratios with 95%
conﬁdence interval (CI) adjusted for confounding factors. Statistical
analysis was performed with STATISTICA 9.0 (StatSoft, Tulsa,
Oklahoma, USA). Two sided p-values <0.05 were considered
statistically signiﬁcant.
Results
A total of 131 PAD patients, mostly hypercholesterolemic and
hypertensive subjects, with a median ABI of 0.72 (Table 1) and tHcy
above 15 mmol l1 (interquartile range, 16.9e20.2 mmol l1)
(Table 2) were studied. Treatment with FA resulted in 70.5%
decrease in tHcy (p < 0.0001). As expected, folate concentrationsTable 2
Baseline laboratory parameters.
Variable The whole Group
(n ¼ 131)
Patients wi
N 3-Hcy-Lys
Total cholesterol, mmol/l 5.0  1.2 4.8  1.0
Low-density lipoprotein
cholesterol, mmol/l
2.9 (2.27e3.4) 2.745 (2.2e
High-density lipoprotein
cholesterol, mmol/l
1.1 (1.0e1.4) 1.1 (1.0e1.
Triglycerides, mmol/l 1.5 (1.1e2.3) 1.3 (0.9e1.
Glucose, mmol/l 5.7 (5.2e6.5) 5.7 (5.3e6.
Creatinine, mmol/l 81 (76e92) 81 (72.8e8
Fibrinogen, g/l 4.0 (2.8e4.9) 4.3 (3.7e4.
CRP, mg/l 2.16 (1.7e3.61) 2.0 (1.3e3.
Interleukin-6, pg/mL 2.2 (1.7e3.3) 2.4 (1.5e4.
Platelets  1000/mL 219.3  64.1 231.3  71
tHcy, mmol/l 18.3 (16.9e20.2) 18.3 (16.5e
Folate, nmol/l 13.9 (10.5e15.9) 12.5 (8.2e1
Plasminogen activator
inhibitor-1, ng/mL
31.7 (26.6e38.4) 44.6 (40.0e
8-iso-prostaglandin
F2a, pg/mL
288.0  89.5 406.8  69
Data shown as mean  SD (Student’s t-test) or as median (IQR; ManneWhitney U test) o
CRP, C-Reactive Protein; tHcy, total homocysteine.increased from a median of 13.9 nmol l1 (10.5e15.9) to
40.8 nmol l1 (37.2e47.0) after the treatment. Detectable serum
N 3eHcyeLys concentrations (median 0.08 mmol l1 (0.05e0.13))
were present in 28 (21.4%) patients, who had 46% higher post-
treatment tHcy (p < 0.0001) as compared with the subjects with
undetectable N 3eHcyeLys (Table 3). Comparison of patients with
detectable N 3eHcyeLys following FA administration with the
remaining subjects (Table 1) showed that the groups differed with
regard to history of prior ischaemic stroke and current smoking.
Routine laboratory variables were similar in both groups except
for slightly lower triglycerides and higher ﬁbrinogen in patients
with detectable N 3eHcyeLys (Table 2). Circulating PAI-1 antigen,
and 8-iso-PGF2a were higher in patients with detectable
N 3eHcyeLys (Table 2). This group had 26.4% higher plasma ADMA
(Table 3).
A 1-year follow-up showed that patients with detectable
N 3eHcyeLys, compared to individuals with non-measurable
N 3eHcyeLys concentrations, more often experienced new MI (12
(43%) vs. eight (8%); p < 0.0001) and stroke (ﬁve (18%) vs. 0 (0%);th detectable
(n ¼ 28)
Patients with undetectable
N 3-Hcy-Lys (n ¼ 103)
p-value
5.1  1.2 0.34
3.4) 2.9 (2.3e3.4) 0.55
4) 1.1 (1e1.3) 0.58
7) 1.5 (1,2e2.4) 0.04
5) 5.7 (5.2e6.8) 0.83
9.5) 82 (76e93) 0.51
9) 3.9 (2.6e4.8) 0.02
7) 2.3 (1.8e3.6) 0.88
4) 2.2 (1.7e3) 0.47
.3 216.0  62.0 0.27
20.5) 18.3 (16.9e20.2) 0.89
5.2) 14 (10.9e16.2) 0.04
49.4) 29.4 (25.3e33) <0.0001
.7 255.7  63.2 <0.0001
r number (percentage; Fisher’s exact test). Abbreviations: ABI, ankle-brachial index;
Table 3
Laboratory and clinical variables in PAD patients after one-year treatment with folic acid.
Variable The whole group
n ¼ 131
Patients with detectable
N 3-Hcy-Lys n ¼ 28
Patients with undetectable
N 3-Hcy-Lys n ¼ 103
p-value
ABI 0.7 (0.6e0.79) 0.62 (0.55e0.71) 0.7 (0.6e0.8) <0.001
L-Arginine, mmol/l 69 (60e76) 71 (64.5e77) 69 (59e74) 0.30
Asymmetric dimethylarginine,
mmol/l
0.56  0.08 0.67  0.04 0.53  0.06 <0.0001
Glutathione, nmol/mL 2.2 (1.7e2.8) 2.5 (2e3.1) 2.1 (1.7e2.7) 0.06
tHcy, mmol/l 5.4 (4.2e6.7) 7.3 (5.6e10) 5 (4.1e6.1) <0.0001
Cysteine, nmol/mL 72.3  20.6 76.4  20.9 71.2  20.4 0.24
Folate, nmol/l 40.8 (37.2e47.0) 39.6 (37.2e48.3) 40.9 (37.0e45.9) 0.74
Data shown as mean  SD (Student’s t-test) or as median (IQR; ManneWhitney U test) or number (percentage; Fisher’s exact test). Abbreviations: ABI, ankle-brachial index;
tHcy, total homocysteine.
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values in subjects with detectable N 3eHcyeLys after FA treatment
(p < 0.001). In this group, we also observed a decline in ABI values
(0.76 (0.67e0.81) to 0.62 (0.55e0.71), p < 0.0001) that was absent
in the remaining patients. PAD progression was observed in four
(14%) individuals with measurable N 3eHcyeLys and there was no
PAD progression observed in the remaining group. Combined end
point of MI, stroke and PAD progression was observed in 75% of
patients with detectable N 3eHcyeLys, as opposed to only 8% in the
remaining individuals. We observed positive correlations between
post-treatment N 3eHcyeLys concentrations and plasma ADMAFigure 1. Correlations between post-treatment N 3eHcyeLys and the following variables: p
glandin F2a (C) and post-treatment ankle-brachial index (D) in patients with PAD (Spearman
isopeptide; ADMA, asymmetric dimethylarginine; PAI-1, plasminogen activator inhibitor-1.(Fig. 1A), glutathione (GSH) (r¼ 0.18; p¼ 0.035) and tHcy (r¼ 0.44;
p < 0.0001) after FA administration. There were also positive
correlations between N 3eHcyeLys and baseline PAI-1 (Fig. 1B), 8-
iso-PGF2a (Fig. 1C) and ﬁbrinogen (r ¼ 0.20; p ¼ 0.019). There was
an inverse correlation between post-treatment N 3eHcyeLys and
ABI after 1 year of follow-up (Fig. 1D).
Multivariate analysis showed that baseline plasma PAI-1 and 8-
iso-PGF2a concentrations were the independent predictors of
presence of measurable N 3eHcyeLys in PAD patients treated with
FA (OR per 1 unit increase (95% CI): 1.24 (1.12e1.52), p < 0.001 and
OR per 1 unit increase (95% CI): 1.03 (1.02e1.07), p < 0.001,ost-treatment plasma ADMA (A), pre-treatment PAI-1(B), pre-treatment 8-iso-prosta-
’s rank correlation coefﬁcient). Abbreviations: N 3eHcyeLys, N 3ehomocysteinylelysine
P. Mazur et al. / European Journal of Vascular and Endovascular Surgery 43 (2012) 588e593592respectively). Subjects receiving angiotensin-converting enzyme
inhibitors (ACEI) (n ¼ 85) were less probable to have a measurable
N 3eHcyeLys concentration (OR (95% CI) ¼ 0.01 (0.0001e0.17);
p < 0.001). After adjustment for demographic confounders and
positive history of stroke, the chance of detection of N 3eHcyeLys in
serum increased with a rise in the baseline concentrations of PAI-1
(OR per 1 unit increase (95% CI): 1.197 (1.093e1.354), p < 0.0001),
8-iso-PGF2a (OR per 10 units increase (95% CI): 1.250 (1.140e1.414),
p < 0.0001), GSH (OR per 0.1 unit increase (95% CI): 1.109
(1.030e1.217), p ¼ 0.005), and post-treatment values of tHcy (OR
95% CI ¼ 2.011 (1.383e3.344), p < 0.0001) and ADMA (OR per 0.05
unit increase (95% CI): 14.833 (4.071e312.157) p < 0.0001).
Discussion
This study demonstrates that the presence of circulating
N 3eHcyeLys isopeptide in PAD patients with hyper-
homocysteinemia during administration of FA that effectively
reduces tHcy is associated with the PAD progression and an
increased risk of cardiovascular events. Moreover, we showed that
in PAD, circulating N 3eHcyeLys isopeptide is associated with
elevated ADMA levels, enhanced oxidative stress and impaired
ﬁbrinolysis reﬂected by increased PAI-1. Our study might help to
understand the failure of studies to yield clinical beneﬁts despite
lowering of tHcy.21,22 Most likely, the presence of circulating
N 3eHcyeLys is largely driven by increased generation of Hcy-
proteins in PAD patients with hyperhomocysteinemia.
Our ﬁndings suggest that the presence of N 3eHcyeLys predis-
poses to cerebrovascular events or it is a marker of previous cere-
bral ischaemia. Detectable N 3eHcyeLys is frequent in current
smokers. Smoking is associated with hyperhomocysteinemia and
oxidative stress.23,24
Moreover, our study provides additional evidence for the asso-
ciation between Hcy and ADMA metabolism in atherosclerosis.
Impaired ﬁbrinolysis attributed to ﬁbrinogen modiﬁcation by
Hcy is supported by our ﬁnding that in PAD patients with
N 3eHcyeLys in blood, plasma PAI-1, typically increased in PAD
patients, positively correlated with N 3eHcyeLys.25,26 The presence
of detectable N 3eHcyeLys was also associated with oxidative
stress, which suggests that N 3eHcyeLys is linked with processes
implicated in cardiovascular disease, including platelet activation.27
Interestingly, the use of ACEI was shown to be an independent
predictor of the absence of measurable N 3eHcyeLys in our study.
ACEIs can lower plasma ADMA and tHcy.28,29 It has been demon-
strated that ramipril may prevent cardiovascular events in PAD
patients.30 This observation merits further investigation.
Our study has several limitations. The number of study partic-
ipants was limited. We determined N 3eHcyeLys solely following
FA administration, therefore we cannot assess the changes in this
parameter during Hcy-lowering therapy. Autoimmune response to
homocysteinylated proteins was not determined.31
In conclusion, in patients with PAD, N 3eHcyeLys measurable in
peripheral blood is associated with cardiovascular events and PAD
progression. Larger studies are needed to assess clinical relevance
of the current ﬁndings.
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